Author of

• 17398

  +

  P2.01 - Poster Session with Presenters Present (ID 461)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17472

    +

    P2.01-074 - Increased AIMP2-DX2/AIMP2 Autoantibody Ratio is Associated with Poor Prognosis in Lung Cancer (ID 4874)

    14:30 - 14:30  |  Author(s): A. Kim
    • Abstract

    Background:
    Aminoacyl t-RNA synthetase-interacting multi-functional proteins (AIMPs) are scaffolding protein required for the assembly of the t-RNA synthetase complex, forming multisynthetase complex. Besides their inherent roles, AIMPs translocate to the other cellular compartments and involve in various cellular pathways. On the other hands, its alternative spliced form lacking exon2 (AIMP2-DX2) compromises the tumor suppressive activity of AIMP2. Recently, presence of autoantibodies against AIMP2-DX2 and AIMP2 were identified in the human blood but its clinical implication is unknown.
    
    Methods:
    The diagnostic usefulness of blood autoantibody against AIMP2-DX2 and AIMP2 was investigated in 80 lung cancer cases and 1:1 age, gender and smoking status matched control cases using ROC curve. To exploit their clinical implication, blood level of autoantibody against AIMP2-DX2, AIMP2 and AIMP2-DX2/AIMP2 ratio was analyzed with clinical parameters in 165 lung cancer patients.
    
    Results:
    There was no statistically significant difference in the blood autoantibody level against AIMP2-DX2 and AIMP2 between lung cancer and control cases. However AIMP2-DX2/AIMP2 ratio was higher in lung cancer patients (30.7±12.6 vs. 39.1±18.4, P=0.001, t-test). When their diagnostic usefulness was evaluated by ROC curve generation, the AUC of auto-antibody level of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio were 0.416, 0.579 and 0.357 respectively, suggesting their diagnostic value in lung cancer is limited. A total 165 lung cancer patients were classified into 2 groups, high and low group, on the basis of median value of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio, respectively, and then further analyzed. There was no statistical difference in the gender, smoking, pathologic diagnosis and stage between high and low group of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio. But AIMP2-DX2 high group was older than those with lower AIMP2-DX2 group (66.8±8.4 vs. 63.8±10.1 years, P-value=0.040, t-test). When the relationship with CEA and CYFRA-21 was evaluated, the AIMP2-DX2/AIMP2 high group showed higher CYFRA-21 level (7.9±12.1 vs. 4.3±4.3 ng/mL, P-value=0.020, χ[2]-test). There was no significant relationship between AIMP2-DX2 and AIMP2 concentration with progression free survival and overall survival. But the patients with high AIMP2-DX2/AIMP2 ratio showed significant short overall survival (18.6 (95% CI: 15.19~22.00) vs. 48.9 (95% CI: 14.89~82.91 months), P-value=0.021, Log-Rank Test).
    
    Conclusion:
    Autoantibodies against AIMP2-DX2 and AIMP2 exist at detectable level in human blood. Increased AIMP2-DX2/AIMP2 ratio is closely related to the poor clinical outcome of lung cancer patents, indicating those are warranted for further study for development as biomarkers in lung cancer.